Phase 2 Clinical Trials
Nuvig Therapeutics Secures $161M Funding for Phase 2 Study in Autoimmune Diseases
Nuvig Therapeutics, autoimmune diseases, Phase 2 study, funding, NVG-2089, Chronic Idiopathic Demyelinating Polyneuropathy (CIDP), recombinant Fc Ab fragments, synthetic manufacturing.
Kinevant Sciences Discontinues Namilumab Development for Pulmonary Sarcoidosis Following Phase 2 Failure
Namilumab, Pulmonary Sarcoidosis, Phase 2 Study, Kinevant Sciences, RESOLVE-Lung Study, Anti-GM-CSF Monoclonal Antibody
Lilly’s Muvalaplin Shows Promising Results in Reducing Lipoprotein(a) Levels in Adults at High Risk for Cardiovascular Events
Muvalaplin, Lipoprotein(a) [Lp(a)], Cardiovascular risk, Oral drug, Phase II trial, Eli Lilly, Cholesterol reduction
AbbVie’s Schizophrenia Drug Fails in Phase II Trials, Casting Doubt on Neuroscience Strategy
AbbVie, schizophrenia, emraclidine, Phase II trials, Cerevel Therapeutics, neuroscience strategy, pharmaceutical industry
Intellia’s CRISPR Therapy NTLA-2002 Shows 81% Reduction in Hereditary Angioedema Attacks in Phase 2 Study
CRISPR therapy, Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), Gene editing, Phase 2 study, Swelling attacks, Functional cure
Roche’s Fenebrutinib Shows Promising Results in Relapsing Multiple Sclerosis Phase II Trial
Roche, fenebrutinib, relapsing multiple sclerosis, BTK inhibitor, Phase II trial, FENopta study
NuCana’s Chemotherapy Replacement Fails to Improve Survival in Phase II Trial
NuCana, chemotherapy replacement, Phase II trial, progression-free survival, colorectal cancer, NUC-3373
MBX Secures $63.5M in Funding Ahead of Clinical Readouts
MBX, clinical readouts, funding, engineered peptide therapeutics, hypoparathyroidism, Phase II trial
Healx Initiates Phase II Trial for AI-Discovered Rare Disease Candidate with $47M Funding
Healx, AI-discovered, rare disease, neurofibromatosis Type 1, Phase II trial, $47M funding
Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease
Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure